P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.
P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.
复制标题
DOI：
10.2147/jpr.s278285
复制
发表时间：
2021
影响因子：
2.7
通讯作者：
Kutlar A
中科院分区：
文献类型：
--
作者：
Karki NR;Kutlar A
微血管闭塞引起的疼痛危象是镰状细胞病的标志，发病率高，死亡率高。选择蛋白，最值得注意的是P-选择蛋白在这种现象中具有不可或缺的作用。P-选择在1989年首次被发现。2019年，经过30年的基础、转化和临床研究，美国食品和药物管理局批准了一种P-选择素抗体crizanlizumab，用于降低16岁以上镰状细胞病患者的疼痛危象频率。我们回顾了P-选择素病理生物学的基本原理，P-选择素阻断剂，使用crizanlizumab的临床数据和这类新型药物在其他治疗疼痛性血管闭塞发作的背景下的前景。
Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the fundamentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.